Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM